describe uses of growth hormone and somatropin in different conditions with dose and rationality
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed
"growth hormone" AND "somatropin" AND therapy
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Here is a detailed synthesis:
Growth Hormone (Somatropin) — Uses, Doses, and Rationale
Overview
Somatropin is recombinant human growth hormone (rhGH) whose sequence matches native GH. It acts through GH receptors to stimulate hepatic production of insulin-like growth factor-1 (IGF-1), which mediates most of its anabolic and growth-promoting effects. Administered subcutaneously (bioavailability ~70%), it has a plasma half-life of only ~20 minutes but a much longer biological half-life, allowing once-daily dosing in most preparations. The evening is the preferred administration time to mimic the physiologic nocturnal GH surge.
FDA-Approved Indications
1. GH Deficiency in Children (Pituitary Dwarfism)
Rationale: GH is essential for linear bone growth via IGF-1. Deficiency causes proportionate short stature, delayed bone maturation, increased central adiposity, and hypoglycemia in infants. Since GH stimulates chondrocyte proliferation in open epiphyseal plates, replacement restores normal growth velocity.
Dose:
- Somatropin: 20–35 μg/kg/day SC, given in 6–7 divided daily doses (or once daily at bedtime)
- At puberty, dose is often increased to 70 μg/kg/day while monitoring serum IGF-1 and IGFBP-3 (target: no more than +2 SD above upper limit of normal)
- Lonapegsomatropin (long-acting, once-weekly): 0.24 mg/kg/week — now preferred over daily somatropin
Monitoring: Average growth of 9–10 cm in year 1, then 6–7 cm/year for next 2 years. Check thyroid function if growth slows. Treat until growth velocity <2.0–2.5 cm/year or target height reached. Discontinue when epiphyses close.
2. GH Deficiency in Adults
Rationale: Adult-onset GHD (from surgery, trauma, radiation, or pituitary disease) causes generalized obesity, reduced lean muscle mass, asthenia, reduced bone mineral density, dyslipidemia, impaired cardiac output, and diminished quality of life. GH replacement reverses many of these metabolic derangements.
Dose:
- Somatropin: Start at 150–300 μg/day SC (or 2.0–5.0 μg/kg/day), titrate by 100–200 μg/day increments every 2 months targeting mid-normal serum IGF-1 for age
- Women on oral estrogen require higher doses (typically 3.0 μg/kg/day for premenopausal or oral-estrogen users) due to first-pass hepatic blunting of GH action
- Somapacitan (long-acting weekly analog): Start at 1.5 mg/week SC; increase by 0.5–1.5 mg increments up to maximum 8 mg/week
- Evening administration preferred to mimic physiologic diurnal rhythm
3. Turner Syndrome
Rationale: Girls with 45,X karyotype have short stature despite normal GH levels due to haploinsufficiency of the SHOX gene and partial GH resistance. Exogenous GH overcomes receptor resistance and promotes linear growth. Combined judiciously with low-dose estrogen to optimize both height and secondary sexual development.
Dose: 50–67 μg/kg/day SC (higher than standard GH-deficiency dose to overcome partial resistance)
Expected benefit: Average increase in adult height of 10–15 cm (4–6 inches) vs. untreated controls.
4. Noonan Syndrome
Rationale: Autosomal dominant syndrome with short stature, characteristic facies, and cardiac defects. Growth failure is multifactorial; GH therapy improves height similarly to Turner syndrome due to partial GH resistance.
Dose: 50–67 μg/kg/day SC
5. Prader-Willi Syndrome (PWS)
Rationale: PWS is an autosomal dominant disorder with GH deficiency, severe obesity, and carbohydrate intolerance. GH therapy reduces body fat, increases lean mass, linear growth, and energy expenditure. However, this indication requires careful patient selection.
Dose: 25–50 μg/kg/day SC
Critical contraindication: GH is contraindicated in PWS patients who are severely obese or have severe respiratory impairment — sudden deaths have occurred due to increased risk of asphyxia/sleep apnea.
6. Chronic Renal Insufficiency (Pre-transplant)
Rationale: CRI suppresses the GH-IGF-1 axis and causes uremia-related growth failure in children. Exogenous GH can restore growth velocity by overcoming IGF-1 resistance at the tissue level.
Dose: 50 μg/kg/day SC (pre-transplant); discontinued after renal transplant with adequate function.
7. SHOX Gene Deficiency
Rationale: Haploinsufficiency of the short stature homeobox gene (SHOX) on the X chromosome causes short stature. GH therapy increases height through IGF-1-mediated chondrogenesis.
Dose: 50 μg/kg/day SC
8. Small for Gestational Age (SGA) with Failure to Catch Up
Rationale: Most SGA infants catch up by age 2, but ~10–15% do not. These children often have relative GH resistance. Exogenous GH promotes catch-up growth when administered before epiphyseal fusion.
Criteria: Height remains >2 SD below normal at age 2 years
Dose: 35–70 μg/kg/day SC
9. Idiopathic Short Stature (ISS)
Rationale: A controversial but FDA-approved use. ISS is defined as height ≥2.25 SD below mean for age and sex with no identifiable cause. GH therapy modestly increases final adult height.
Dose: 50–67 μg/kg/day SC
Expected benefit: Average adult height gain of only 4–7 cm after many years of treatment, at significant cost ($5,000–$40,000/year). The risk-benefit ratio is debated.
10. AIDS-Associated Wasting/Cachexia
Rationale: HIV-associated wasting (involuntary weight loss >10% with diarrhea or weakness) involves loss of lean body mass driven by catabolic cytokines and poor nutritional state. GH has net anabolic effects — it promotes nitrogen retention, increases lean body mass, and improves physical endurance by stimulating protein synthesis via IGF-1.
Dose: GH is approved at 4–6 mg/day SC for HIV-associated wasting
Monitoring: Regular assessment of lean/fat mass and quality-of-life metrics.
11. Short Bowel Syndrome (SBS)
Rationale: After extensive intestinal resection, GH stimulates GI epithelial adaptation, increasing intestinal villous height and improving absorptive surface area. It is used in conjunction with glutamine (an intestinal fuel) and specialized nutritional support to reduce dependence on total parenteral nutrition (TPN).
Approval: FDA-approved in 2004 for TPN-dependent SBS patients
Dose: 0.1 mg/kg/day SC (up to 8 mg/day) for a limited course
Caveat: Clinical benefits have mostly been short-lived in published studies.
Long-Acting Formulations
| Agent | Mechanism | Dose | Indication |
|---|---|---|---|
| Lonapegsomatropin | PEGylated GH (weekly) | 0.24 mg/kg/week SC | Pediatric GHD (preferred over daily somatropin) |
| Somapacitan | Albumin-binding GH analogue (weekly) | 1.5–8 mg/week SC | Adult GHD |
Off-Label and Controversial Uses
| Use | Evidence | Comment |
|---|---|---|
| Anti-aging | Unsubstantiated | Risks (carpal tunnel, edema, glucose intolerance) outweigh benefits; paradoxically, animal data show GH/IGF-1 signaling shortens lifespan |
| Athletic performance enhancement | No proven benefit | Banned by International Olympic Committee |
| Fibromyalgia | Weak/insufficient | Some GHD features overlap with fibromyalgia; trials have been small |
Adverse Effects
| Category | Effects |
|---|---|
| Children | Pain at injection site, pseudotumor cerebri (papilledema, headache), slipped capital femoral epiphysis, scoliosis progression, edema, hyperglycemia |
| Adults | Peripheral edema, carpal tunnel syndrome, arthralgias, myalgias (especially hands/wrists), glucose intolerance — usually dose-dependent and resolve with dose reduction |
| Metabolic | Increased cortisol inactivation (can unmask adrenal insufficiency); reduced insulin sensitivity (adjust diabetes medications); increased CYP450 activity (may lower levels of co-administered drugs) |
Key Contraindications
- Active malignancy (absolute contraindication)
- Closed epiphyses in children (for growth purposes)
- Proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy
- Severely obese or respiratory-impaired patients with Prader-Willi syndrome
- Acute critical illness (post-cardiac/abdominal surgery, severe trauma, acute respiratory failure)
- First year post-treatment of pediatric CNS tumors (leukemia, medulloblastoma)
Summary Table
| Condition | Population | Daily Dose | Key Rationale |
|---|---|---|---|
| GH deficiency | Children | 20–35 μg/kg/day SC | Replace deficient GH; restore growth |
| GH deficiency (puberty) | Adolescents | Up to 70 μg/kg/day SC | Overcome pubertal GH surge requirement |
| GH deficiency | Adults | 150–300 μg/day (start) | Restore metabolic health, body composition |
| Turner syndrome | Girls | 50–67 μg/kg/day SC | Overcome SHOX/GH resistance |
| Noonan syndrome | Children | 50–67 μg/kg/day SC | Overcome partial GH resistance |
| Prader-Willi syndrome | Children | 25–50 μg/kg/day SC | Decrease fat, increase lean mass |
| Chronic renal insufficiency | Children (pre-transplant) | ~50 μg/kg/day SC | Overcome uremic IGF-1 resistance |
| SGA (no catch-up by age 2) | Children | 35–70 μg/kg/day SC | Promote catch-up growth |
| Idiopathic short stature | Children | 50–67 μg/kg/day SC | Modest height gain (controversial) |
| AIDS wasting | Adults | 4–6 mg/day SC | Anabolic effect; increase lean body mass |
| Short bowel syndrome | Adults on TPN | ~0.1 mg/kg/day SC | Stimulate GI epithelial adaptation |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology; Goldman-Cecil Medicine
WHAT ABOUT severe burns, bedridden patients
Checking Date & Time
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
"growth hormone" AND "burn" AND children
Reading File
Reading Article
Now I have a thorough picture. Here is the focused answer:
Growth Hormone in Severe Burns and Bedridden/Critically Ill Patients
Pathophysiology: Why the GH Axis Is Disrupted
Severe injury triggers a biphasic response:
- Phase 1 (0–72 hours): Hypodynamic shock state — low cardiac output, reduced perfusion
- Phase 2 (from ~day 5): Hyperdynamic hypercatabolic state — supraphysiologic cardiac output, elevated body temperature, markedly increased REE, accelerated muscle proteolysis, insulin resistance, and hyperglycemia
The catabolic state is driven by a massive surge of cortisol, glucagon, and catecholamines. Paradoxically, although GH levels may be elevated acutely, IGF-1 and IGFBP-3 levels plummet — the liver becomes resistant to GH signaling, so the anabolic arm of the GH axis is functionally suppressed. This is the rationale for supplementing rhGH.
GH in Severely Burned CHILDREN — Beneficial
This is the clearest evidence-backed use outside of GH deficiency.
Evidence:
- Pediatric burn patients receiving rhGH showed markedly improved growth, lean body mass, and significant attenuation of hypermetabolism, associated with significant increases in serum GH, IGF-1, and IGFBP-3
- Among pharmaceutical interventions tested in thermal injury (GH, IGF-1, oxandrolone, propranolol, insulin), propranolol and oxandrolone have demonstrated the most significant clinical impact in current surgical practice, but rhGH in children has proven benefits
Dose used in pediatric burn trials:
- rhGH 0.05–0.2 mg/kg/day SC, initiated within the first week after burns covering >40% TBSA, continued through the acute and post-acute phases
- Some protocols continue for up to 12 months post-burn to counter the persistent hypermetabolic state
Rationale: Children are still in a growth phase. Burn-induced catabolism can permanently impair linear growth and lean mass development. rhGH restores the GH-IGF-1 axis, promotes protein synthesis, and attenuates muscle proteolysis during the prolonged catabolic window.
GH in Critically Ill ADULTS — Contraindicated / Harmful
This is a critical safety point backed by a landmark RCT.
The Takala et al. 1999 Trial (N Engl J Med):
A large, prospective, randomized trial administered high-dose rhGH to critically ill adult ICU patients (post-cardiac surgery, abdominal surgery, trauma, respiratory failure). Results:
- Significantly increased mortality in the GH-treated group
- Prolonged ventilator dependence
- Increased susceptibility to infection (sepsis)
Additionally, a study of 103 consecutive critically ill adults found that circulating GH levels were ~7× higher in non-survivors than survivors on admission — indicating that in this setting, GH elevation is a marker of severity, not a deficiency to correct.
Current consensus (Barash Clinical Anesthesia):
"GH administration during critical illness cannot be advocated at this time."
Mechanism of harm: High-dose GH in critical illness worsens hyperglycemia and insulin resistance (already a feature of critical illness), impairs immune function, and may promote excessive anabolism that the stressed system cannot support.
Formal contraindication (Goodman & Gilman): rhGH is contraindicated in patients with:
- Acute critical illness due to complications after open heart or abdominal surgery
- Multiple accidental trauma
- Acute respiratory failure
GH in Bedridden / Immobilized Patients (Disuse Atrophy)
GH is not a standard or approved therapy for bedridden patients with disuse muscle atrophy (e.g., prolonged ICU stay, neurologic immobility, post-fracture immobilization).
Rationale against routine use:
- The immobility-associated catabolic state shares features with critical illness; the safety signal from the Takala trial generalizes to other adult catabolic states
- GH's anabolic effect requires intact downstream signaling (IGF-1 responsiveness), which is impaired during prolonged illness
- GH worsens glucose intolerance, which is already prevalent in bedridden patients
What is used instead:
- Oxandrolone (anabolic androgen, 0.1 mg/kg q12h) — reduces muscle catabolism, improves lean mass
- Propranolol (non-selective β-blocker) — attenuates catecholamine-driven catabolism and hypermetabolism
- Early enteral nutrition with high protein (1.5–2 g/kg/day)
- Glutamine supplementation — benefits shown in burns and select ICU populations
- Insulin (tight-to-moderate glycemic control) — counters hyperglycemia-driven catabolism
Summary Table
| Clinical Context | GH Use | Evidence | Current Recommendation |
|---|---|---|---|
| Severe burns — children | Beneficial | RCTs, positive | Used adjunctively; 0.05–0.2 mg/kg/day SC; attenuates hypermetabolism, restores growth |
| Severe burns — adults | Harm risk | Extrapolated from critical illness data; indeterminate per some surgical texts | Not routinely used; oxandrolone + propranolol preferred |
| Critically ill adults (ICU/surgery/trauma) | Contraindicated | Large RCT (Takala 1999) — increased mortality | Absolutely contraindicated |
| Bedridden / immobilized patients | Not standard | No strong evidence; safety concerns | Not recommended; use nutritional and anabolic strategies instead |
| Prolonged post-burn recovery (>30% TBSA) | Investigational | Pediatric data positive; adult data indeterminate | Oxandrolone for 6 months is current standard; GH adjunctive only in children |
Bottom line: rhGH has a genuine role in pediatric burn patients to counter the prolonged hypermetabolic/catabolic injury response. In adult critically ill patients, it is contraindicated based on a definitive mortality signal. For bedridden adults, anabolic steroids (oxandrolone), beta-blockade, insulin, and aggressive nutrition remain the standard of care.
Sources: Schwartz's Principles of Surgery 11th Ed.; Sabiston Textbook of Surgery; Mulholland & Greenfield's Surgery 7th Ed.; Barash Clinical Anesthesia 9th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics; [Cuijpers et al., Burns 2024, PMID 38580580]
what about sermorelin
Finding Sources
Searching PubMed
sermorelin AND "growth hormone"
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Searching the Web
sermorelin clinical uses dose mechanism FDA status 2024
Searching PubMed
sermorelin AND ("growth hormone deficiency" OR diagnosis OR therapy)
Reading Article
Finding Sources
Good. I now have sufficient data. Let me synthesize everything into a comprehensive answer.
Sermorelin — Mechanism, Uses, Dose, and Regulatory Status
What Is Sermorelin?
Sermorelin (also written as sermorelin acetate) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It is a truncated 29-amino acid peptide corresponding to the first 29 amino acids of the naturally occurring 44-amino acid GHRH — and this 1–29 fragment retains full biological activity at the GHRH receptor.
Mechanism of Action
GHRH is produced by arcuate nucleus neurons in the hypothalamus. It reaches pituitary somatotropes via the hypophyseal portal blood and binds a specific Gs-coupled GPCR (GHRH receptor). This:
- Raises intracellular cAMP and Ca²⁺
- Stimulates GH synthesis and pulsatile secretion from somatotropes
- Downstream GH then stimulates hepatic IGF-1 production, which mediates anabolic/growth effects
Key distinction from somatropin (rhGH):
- Sermorelin acts upstream at the hypothalamic-pituitary axis — it stimulates the pituitary to produce GH endogenously
- It therefore preserves the normal pulsatile pattern of GH release and retains negative feedback (somatostatin, IGF-1), making oversecretion self-limiting
- Somatropin bypasses this entirely — it directly replaces GH regardless of pituitary reserve
FDA Regulatory Status
| Agent | Status |
|---|---|
| Sermorelin | Previously FDA-approved (Geref) for GH deficiency testing and pediatric GH deficiency; withdrawn from US market in 2008 (commercial reasons, not safety); now exists as a compounded preparation only |
| Tesamorelin (GHRH analogue, N-terminally modified, DPP-4 resistant) | FDA-approved (Egrifta SV) for HIV-associated lipodystrophy |
| Macimorelin (GH secretagogue/ghrelin mimetic) | FDA-approved for GH deficiency diagnostic testing only |
Sermorelin is no longer commercially available as an FDA-approved product in the US. It is widely compounded and used off-label through anti-aging/wellness clinics, which is a point of regulatory concern.
Clinical Uses
1. Diagnosis of GH Deficiency (Historical Primary Indication)
Rationale: Since GH is secreted episodically, a random serum GH is unreliable. Sermorelin (like GHRH) was used as a provocative stimulus — administering 1 μg/kg IV and measuring peak serum GH levels. A blunted response (<10 ng/mL) confirmed somatotroph dysfunction.
This has largely been supplanted by insulin tolerance testing (ITT), glucagon stimulation, and now macimorelin (oral, FDA-approved 2017) for adult GHD diagnosis.
2. Pediatric GH Deficiency (Historical Therapeutic Use)
Dose: 30 μg/kg/day SC at bedtime
Rationale: For children with hypothalamic (GHRH-deficient) causes of GH deficiency — where the pituitary somatotropes are intact but not receiving adequate GHRH stimulus — sermorelin restimulates endogenous GH release. It was found to increase linear growth velocity and IGF-1 levels.
Limitation: If the pituitary itself is damaged (e.g., post-surgery, radiation, pituitary aplasia), sermorelin is ineffective because it requires functional somatotropes. In these cases, somatropin is required.
3. HIV-Associated Lipodystrophy — Tesamorelin (GHRH Analogue)
The related GHRH analogue tesamorelin is FDA-approved for this indication:
- Dose: 2 mg SC daily
- Mechanism: Stimulates pulsatile GH → IGF-1 → lipolysis of visceral adipose tissue
- Effect: Primarily reduces excess visceral/abdominal fat (lipohypertrophy) with minimal effect on insulin resistance
- Sermorelin is used off-label for the same purpose in compounding settings but lacks the regulatory approval of tesamorelin
4. Off-Label and Compounded Uses (Anti-Aging / Wellness Market)
This is where most current sermorelin use occurs, though evidence is limited:
| Use | Claimed Benefit | Evidence Level |
|---|---|---|
| Age-related GH decline | Restore IGF-1 levels, improve body composition, bone density | Very limited; unsubstantiated for "anti-aging" |
| Adult GHD (mild/partial) | Improve lean mass, energy, quality of life | Small trials; not FDA-approved |
| Athletic performance | Increased muscle mass, recovery | No proven benefit; banned by WADA/IOC |
| Obesity / metabolic syndrome | Reduce visceral fat | Theoretical; insufficient human data |
| Sleep quality | GH is released during slow-wave sleep; GHRH promotes sleep | Small studies only |
Critical caveat: The 2026 Sports Medicine review (Mendias & Awan) categorizes sermorelin among unapproved peptides in the "gray market" — animal model data may appear favorable but rigorous human safety data are scarce, and the social media-amplified placebo effect contributes heavily to perceived benefit.
Sermorelin vs. Somatropin vs. Tesamorelin — Comparison
| Feature | Sermorelin | Somatropin (rhGH) | Tesamorelin |
|---|---|---|---|
| Class | GHRH analogue (1–29 fragment) | Recombinant human GH | GHRH analogue (N-modified, DPP-4 resistant) |
| Site of action | Pituitary (stimulates GH release) | GH receptors peripherally | Pituitary (stimulates GH release) |
| GH pattern | Preserves pulsatile secretion | Continuous supraphysiologic level | Pulsatile (more physiologic) |
| Negative feedback | Intact (self-limiting via IGF-1/SST) | Bypassed | Intact |
| Requires intact pituitary | Yes | No | Yes |
| Half-life | ~12 minutes SC | ~20 min (plasma); longer biologic t½ | Longer (DPP-4 resistant) |
| FDA status | Withdrawn 2008; compounded only | FDA-approved (multiple brands) | FDA-approved (Egrifta SV) |
| Main current use | Compounded off-label | GHD, short stature, AIDS wasting, SBS | HIV lipodystrophy |
| Cost | Lower (compounded) | High | High |
Adverse Effects of Sermorelin
- Injection site reactions (redness, swelling, pain) — most common
- Flushing, headache, dizziness
- Hyperglycemia (via GH-mediated insulin resistance) — less pronounced than direct GH because of feedback control
- Fluid retention, edema (less than somatropin)
- Anti-sermorelin antibodies can develop but are generally non-neutralizing
- Theoretical risk of pituitary adenoma stimulation with long-term use — not confirmed in clinical data
Bottom Line
Sermorelin is a physiologically elegant approach — it nudges the pituitary to produce its own GH rather than replacing it directly, preserving feedback regulation and a pulsatile pattern. Its historical FDA approval was for pediatric GHD and diagnostic testing; it was withdrawn for commercial, not safety, reasons. Today it exists almost entirely as a compounded anti-aging product with limited rigorous evidence to support most off-label uses.
For clinical GHD therapy, somatropin or lonapegsomatropin remains the standard. For HIV lipodystrophy, tesamorelin (FDA-approved) is the preferred GHRH-axis agent.
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Goldman-Cecil Medicine; Katzung's Basic & Clinical Pharmacology 16th Ed.; Mendias & Awan, Sports Med 2026 [PMID 41966639]
This is a shared conversation. Sign in to Orris to start your own chat.